Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adamas Pharmaceuticals has declared the results of a preclinical study that indicated the collaborative effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.
Subscribe to our email newsletter
The results of the study have been published in PLoS One under the title: Triple Combination of Amantadine, Ribavirin, and Oseltamivir is Highly Active and Synergistic Against Drug Resistant Influenza Virus Strains In Vitro. PLoS One is an interactive open-access journal for the communication of all peer-reviewed scientific and medical research published by the Public Library of Science (PLoS).
The data indicated that amantadine, ribavirin and oseltamivir, when administered as components of a triple combination therapy, had a collaborative effect of enhancing antiviral activity against multiple amantadine- and oseltamivir-resistant virus strains.
The data also demonstrated that the antiviral activity of the TCAD regimen is greater than the antiviral activity of any double combination. In addition, when investigating amantadine-resistant virus strains against which amantadine had no significant antiviral activity as a single agent, by adding amantadine at clinically relevant concentrations to the combination of ribavirin and oseltamivir, it resulted in a dose dependent inhibition of virus replication.
The reaction was similarly observed for oseltamivir in strains that were oseltamivir resistant. According to the data, the TCAD therapy may have broad-spectrum activity against the circulating resistant influenza A strains, including novel influenza A/H1N1, the pandemic influenza strain.
Gregory Went, CEO and chairman of Adamas Pharmaceuticals, said: “Given the fact that the majority of influenza A viruses are resistant to at least one antiviral, these data suggest the advantage of a triple combination drug therapy approach over double combinations or monotherapy. We are encouraged about the potency of TCAD therapy measured in preclinical studies and look forward to continued validation of TCAD therapy with our academic and clinical partners.”